Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Johnson & Johnson's TREMFYA (guselkumab) gains FDA label expansion for structural joint damage inhibition in active psoriatic arthritis
Antibody, autoimmune, monoclonal antibody, psoriatic arthritis, IL-23 inhibitor, CD64 - Read more

Servier acquires Edgewise Therapeutics' muscular dystrophy unit for $1.55B upfront, $1.1B milestones
Acquisition, rare disease, neuromuscular, small molecule, milestone payments - Read more

Eli Lilly, Haisco Pharmaceutical ink 5-program R&D pact, $87M upfront, up to $3B milestones
Research collaboration, multi-therapeutic, milestone payments, royalties, R&D - Read more

Eli Lilly, Hanmi Pharm license GLP-2 agonist sonefpeglutide, $75M upfront, up to $1.2B deal
Licensing deal, rare disease, peptide, milestone payments, metabolic disease - Read more

Circio, GenAssist collaborate on circVec-enhanced AAV gene therapy for muscle diseases and in vivo CAR-T
Research collaboration, gene therapy, rare disease, oncology, autoimmune, cell therapy - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Gilead's TUB-040 (NaPi2b-targeting ADC) shows 61% tumor response in Ph1 platinum-resistant ovarian cancer trial
Antibody-drug conjugate, cancer, ADC, ovarian cancer, NaPi2b target, platinum-resistant - Read more

Incyte's Monjuvi (tafasitamab) combo shows Ph3 progression-free survival benefit in first-line diffuse large B-cell lymphoma
Antibody, cancer, monoclonal antibody, diffuse large B-cell lymphoma, CD19, combination therapy - Read more

Eli Lilly's Retevmo (selpercatinib) Ph3 data shows 83% reduced recurrence risk in early-stage RET fusion-positive non-small-cell lung cancer
Small molecule, cancer, kinase inhibitor, non-small cell lung cancer, RET fusion, adjuvant therapy - Read more

Pfizer's Talzenna (talazoparib) plus Xtandi (enzalutamide) halves progression risk in metastatic castration-sensitive prostate cancer in Ph3
Small molecule, cancer, PARP inhibitor, prostate cancer, combination therapy, HRR mutation - Read more

Eli Lilly's Kelonia Therapeutics' (KLN-1010) shows 100% response rate in Ph1 relapsed or refractory multiple myeloma trial
Cell therapy, cancer, CAR-T, multiple myeloma, BCMA target, in vivo CAR-T - Read more

Johnson & Johnson's Erleada (apalutamide) cuts metastasis risk 20% in high-risk localised prostate cancer in Ph3 trial
Small molecule, cancer, androgen receptor inhibitor, prostate cancer, androgen deprivation therapy, combination therapy - Read more

AstraZeneca's Imfinzi (durvalumab), Imjudo (tremelimumab) STRIDE regimen improves progression-free survival in unresectable hepatocellular carcinoma in Ph3
Antibody, cancer, monoclonal antibody, hepatocellular carcinoma, PD-L1, CTLA-4 - Read more

Merck & Co.'s (sacituzumab tirumotecan) shows Ph3 overall survival advantage in first-line non-small cell lung cancer
Antibody-drug conjugate, cancer, small molecule, non-small cell lung cancer, TROP2, combination therapy - Read more

Immuneering's atebimetinib (MEK inhibitor) shows 17.3-month survival in Ph2a metastatic pancreatic cancer trial
Small molecule, cancer, MEK inhibitor, pancreatic cancer, combination therapy, chemotherapy - Read more

Revolution Medicines' daraxonrasib nearly doubles survival in Ph3 metastatic pancreatic cancer with KRAS mutation
Small molecule, cancer, KRAS inhibitor, pancreatic cancer, RAS mutation - Read more

Akeso and Summit Therapeutics' (ivonescimab) Ph3 trial shows survival benefit in advanced non-small cell lung cancer
Antibody, cancer, bispecific antibody, non-small cell lung cancer, PD-1/VEGF inhibitor, combination therapy - Read more

AstraZeneca's (anselamimab) Ph3 subgroup data show survival benefit in kappa light chain amyloidosis
Antibody, cardiovascular, monoclonal antibody, AL amyloidosis, amyloid fibril targeting, rare disease - Read more

Eli Lilly's Verzenio (abemaciclib) hits Ph3 milestone in recurrent dedifferentiated liposarcoma targeting CDK4
Small molecule, cancer, CDK4/6 inhibitor, liposarcoma, CDK4 amplification - Read more

Immunocore presents Ph1 (brenetafusp) data showing disease control in heavily pretreated advanced melanoma patients
Small molecule, cancer, bispecific T cell engager, melanoma, anti-PD-1 resistance, combination therapy - Read more

Salubris Biotherapeutics reports Ph1/2 data for (JK06), 5T4-targeted antibody drug conjugate, in unresectable locally advanced or metastatic solid tumors
Antibody drug conjugate, cancer, ADC, non-small cell lung cancer, breast cancer, 5T4 target - Read more

TYK Medicines' asandeutertinib (TY-9591) beats Tagrisso in Ph2 trial for EGFR-mutated non-small-cell lung cancer with brain metastases
Small molecule, cancer, EGFR inhibitor, non-small cell lung cancer, brain metastases - Read more

TheraPPI Bioscience closes Pre-Seed round to advance ERK/MyD88 oncology program
Oncology, rare disease, small molecule, protein-protein interaction, preclinical, Ras-MAPK pathway - Read more

Oak Hill Bio raises $32.5M Series A to advance rugonersen to Phase 3 in Angelman syndrome
Rare disease, antisense oligonucleotide, neurological, clinical-stage - Read more

Legend Biotech founder launches Wondercel Therapeutics with non-gene-editing, high-yield off-the-shelf CAR-T platform
CAR-T, oncology, manufacturing scalability, competitive - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Oculis' OCS-01 (dexamethasone) eye drops fail Ph3 trials for diabetic macular oedema
Small molecule, metabolic, eye drop, diabetic macular oedema, dexamethasone, corticosteroid - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here